This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
None
None
Single group
Anticoagulation Therapy
DrugPatients will be enrolled after at least 3 months of therapeutic anticoagulation for an acute catheter-related upper extremity DVT while they are treated with therapeutic anticoagulation as standard of care. After enrollment, patients will be managed with prophylactic dose of anticoagulation as long as either a CVC or active cancer is present. If cancer goes into remission, at the time of CVC removal, anticoagulation will be stopped, but patients will continue to be followed until the end of the study at 6 months.
Venous Thromboembolism (VTE) Rate
The rates of symptomatic, objectively confirmed new or recurrent major VTE (proximal upper or lower extremity DVT, segmental or larger pulmonary embolism (PE)) with corresponding 95% Confidence Interval (CI) at 6 months.
Major Venous Thromboembolism (VTE) and Major bleeding Rate
Rates of new/recurrent symptomatic major VTE and major bleeding at 3 months.
New/recurrent symptomatic catheter-related upper extremity Deep Vein Thrombosis (DVT).
New/recurrent symptomatic catheter-related upper extremity DVT.
New incidental Venous Thromboembolism (VTE)
New incidental VTE (PE or upper or lower extremity DVT), defined as VTE diagnosed on imaging studies obtained not for concern of VTE, such as cancer staging scans.
New Deep Vein Thrombosis (DVT)
New/recurrent any distal upper or lower extremity DVT or subsegmental PE.
Click on the lead sponsor to view all of their trials.
